Wound Management Technologies, Inc. Subsidiary Wound Care Innovations Signs Agreement to Launch Direct Response Television Advertising Campaign and Online Marketing of CellerateRx®

Thursday, July 1, 2010 Corporate News
Email Print This Page Comment bookmark
Font : A-A+

FORT WORTH, Texas, July 1 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) announced

an important milestone in its planned growth strategy.  Its wholly owned subsidiary Wound Care Innovations signed a distribution agreement with KOMED, LLC of Georgia for direct response advertising on television and niche
online marketing of CellerateRx® in the United States.  TV Goods Holding Corporation (TV Goods), a subsidiary of H&H Imports, Inc., will produce and air the commercials marketing CellerateRx® in cooperation with KOMED, LLC. "KOMED is very excited about the opportunity to market and sell CellerateRx because it is very user friendly and represents a true advancement in collagen based wound care products.  CellerateRx should exceed expectations of both clinicians and patients in the wound healing process," stated Jeff Koblitz, President.

"Our management team is pleased to be working with KOMED and Kevin Harrington's team at TV Goods to be launching CellerateRx® directly to US consumers. We are all very excited about what this deal means for our company's top-line revenue expansion as we pursue retail channels in the United States," stated Ronald Mathis, Wound Care Innovations' Senior Vice President of Marketing and Sales.

Kevin Harrington, CEO of TV Goods, was quoted as saying, "I am so thrilled about working with CellerateRx. The opportunities are huge and offer tremendous revenue opportunities worldwide." Kevin Harrington is widely acknowledged as the pioneer and principal architect of the "infomercial" industry. Since producing the industry's first infomercial in the 1980s, Harrington has financed more than 500 product launches resulting in sales of more than $4 billion worldwide with 20 products reaching individual sales of over $100 million each, and creating dozens of millionaires.  Steve Rogai, President of TV Goods, also added, "We couldn't be more excited to partner with CellerateRx.  We love this product and are looking forward to a global launch and mass retail distribution."

For Wound Management Technologies Shareholder Information please call 817-820-7077 or go to http://www.wmgtech.com

About TV Goods Holding Corporation

TV Goods is a Florida corporation located in Clearwater, Florida which develops, markets and distributes products and services primarily through infomercials and other direct response channels of distribution. TV Goods intends to leverage the experience and current high profile of its chairman, Kevin Harrington, and his management team to develop and launch marketing campaigns for a portfolio of products and services. Mr. Harrington has most recently appeared as one of the stars on ABC's reality TV show "Shark Tank".

About H & H Imports, Inc.

H&H is subject to the reporting requirements of the Securities and Exchange Commission and its common stock is quoted on the Over-the-Counter Bulletin Board (OTC Bulletin Board: HNHI). H&H was organized under the laws of the state of Florida to purchase and sell at wholesale women's handbags and other leather products recently introduced products into the marketplace.

About Wound Care Innovations, LLC

Wound Care Innovations, LLC (WCI) is a wholly owned subsidiary of Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida. WCI markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products.  For more information on CellerateRx, please visit the WCI web site at http://www.celleraterx.com/.

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc.'s primary focus is the distribution of its unique, patented collagen product, CellerateRx®, in the $3.2B worldwide advanced wound care market, a market that is growing due to aging populations and the increase of diabetes.  Over the past 2 years WMT has focused on developing evidenced-based studies on CellerateRx and gaining physician awareness by participation in key industry conferences. Now WMT is focused on expanding sales through partnerships and contracted independent representatives. WMT has other advanced biotech products in development for bone wax, bone void fillers and shingles pain reduction as well as a subsidiary focused on eHealth technology for secure healthcare data collaboration and storage.  More information can be found on the company's web sites: http://www.wmgtech.com, http://www.celleraterx.com , and http://www.secureehealth.com .

Safe Harbor Statement:

The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

CONTACT: Shareholder Relations-Communications, +1-817-820-7077

SOURCE Wound Management Technologies, Inc.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store